Cristina D. D. H. R.
- Country
- Spain
- Department
- Pediatric Hematology and Oncology
Research Overview
- Randomized Phase 3 Trial of Venetoclax Added to Fludarabine, High‑Dose Cytarabine, and Gemtuzumab Ozogamicin in Children with Relapsed Acute Myeloid Leukemia
- Phase 3 Multicenter Study of Ravulizumab Plus Best Supportive Care in Pediatric Patients with HSCT-Associated Thrombotic Microangiopathy
- Phase I/II Evaluation of Inotuzumab Ozogamicin Monotherapy and Combined Chemotherapy in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 60 of 96 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various forms of acute leukemia, with particular emphasis on refractory and relapsed cases in pediatric populations. Their work encompasses both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), including cases with specific genetic mutations.
- FLT3-positive AML treatment approaches
- CD19-positive B-cell ALL therapy
- CD22-positive relapsed/refractory ALL
Cell-Based Therapies
The investigator focuses on innovative cellular therapy approaches, particularly in the development and implementation of CAR-T cell treatments and stem cell transplantation techniques. Their research includes long-term follow-up studies of cellular therapy outcomes.
- Autologous T-cell therapy
- Hematopoietic stem cell transplantation
- Gene therapy for rare blood disorders
Blood Disorders
Their expertise extends to treating various hematologic conditions, including both genetic and acquired disorders. The investigator works with sickle cell disease and rare conditions such as atransferrinemia.
- Graft versus host disease management
- Fanconi anemia treatment
- Post-transplant complications
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.